 The first SARS-CoV-2 vaccine available in Italy, BNT-162B2, has been administered to over 2,000 healthcare professionals at Assistant Fata Benefratelli Sacco Hospital, and a descriptive analysis of safety reports submitted in Udravigilance revealed several new and unexpected adverse reactions that will aid in reviewing the vaccine's safety profile.